Zevra Therapeutics (ZVRA) Change in Accured Expenses (2014 - 2026)

Zevra Therapeutics has reported Change in Accured Expenses for 13 years, with the latest figure at -$529000.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 92.72% year-over-year to -$529000.0; the trailing twelve-month figure through Mar 2026 stood at -$8.9 million (down 148.83% YoY), and the FY2025 full-year result was -$15.6 million, down 333.21% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$529000.0, down from $412000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $7.0 million in Q4 2024, with the low at -$7.3 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged -$320764.7 across 5 years, with a median of -$486000.0 in 2022.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses surged 889.3% — and 2024, when it sank 290.46%.
• Zevra Therapeutics' Change in Accured Expenses stood at $1.9 million in 2022, then surged by 206.58% to $5.7 million in 2023, then gained by 22.02% to $7.0 million in 2024, then slumped by 94.11% to $412000.0 in 2025, then plunged by 228.4% to -$529000.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$529000.0 (Q1 2026), $412000.0 (Q4 2025), and -$4.7 million (Q3 2025), per Business Quant data.